203 related articles for article (PubMed ID: 37852183)
21. [Drug-drug interactions of tyrosine kinase inhibitors in treatment of non-small-cell lung carcinoma].
Libiad Y; Boutayeb S; Chaibi A
Bull Cancer; 2022 Mar; 109(3):358-381. PubMed ID: 35105467
[TBL] [Abstract][Full Text] [Related]
22. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
23. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.
Jahchan NS; Dudley JT; Mazur PK; Flores N; Yang D; Palmerton A; Zmoos AF; Vaka D; Tran KQ; Zhou M; Krasinska K; Riess JW; Neal JW; Khatri P; Park KS; Butte AJ; Sage J
Cancer Discov; 2013 Dec; 3(12):1364-77. PubMed ID: 24078773
[TBL] [Abstract][Full Text] [Related]
24. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
Shoaib M; Kamal MA; Rizvi SMD
Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
[TBL] [Abstract][Full Text] [Related]
25. Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer.
Ochi K; Suzawa K; Tomida S; Shien K; Takano J; Miyauchi S; Takeda T; Miura A; Araki K; Nakata K; Yamamoto H; Okazaki M; Sugimoto S; Shien T; Yamane M; Azuma K; Okamoto Y; Toyooka S
Biochem Biophys Res Commun; 2020 Aug; 529(3):760-765. PubMed ID: 32736704
[TBL] [Abstract][Full Text] [Related]
26. Machine learning driven drug repurposing strategy for identification of potential RET inhibitors against non-small cell lung cancer.
Ramesh P; Karuppasamy R; Veerappapillai S
Med Oncol; 2022 Dec; 40(1):56. PubMed ID: 36542155
[TBL] [Abstract][Full Text] [Related]
27. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
28. Repurposing calcium channel blockers: may be sensible combination with erlotinib for non-small cell lung cancer.
Alandağ C; Merev E; Özdemir F
Anticancer Drugs; 2021 Sep; 32(8):882-885. PubMed ID: 34145175
[TBL] [Abstract][Full Text] [Related]
29. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
30. Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work.
Kumar R; Harilal S; Gupta SV; Jose J; Thomas Parambi DG; Uddin MS; Shah MA; Mathew B
Eur J Med Chem; 2019 Nov; 182():111602. PubMed ID: 31421629
[TBL] [Abstract][Full Text] [Related]
31. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
32. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
[TBL] [Abstract][Full Text] [Related]
33. Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.
Mohi-Ud-Din R; Chawla A; Sharma P; Mir PA; Potoo FH; Reiner Ž; Reiner I; Ateşşahin DA; Sharifi-Rad J; Mir RH; Calina D
Eur J Med Res; 2023 Sep; 28(1):345. PubMed ID: 37710280
[TBL] [Abstract][Full Text] [Related]
34. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
35. Applications of promiscuity of FDA-approved kinase inhibitors in drug repositioning and toxicity.
Korikani M; Fathima N; Nadiminti G; Akula S; Kancha RK
Toxicol Appl Pharmacol; 2023 Apr; 465():116469. PubMed ID: 36918129
[TBL] [Abstract][Full Text] [Related]
36. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
Peters S; Zimmermann S; Adjei AA
Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
[TBL] [Abstract][Full Text] [Related]
37. An updated patent review of small-molecule ROS1 kinase inhibitors (2015-2021).
Liu M; Dai J; Wei M; Pan Q; Zhu W
Expert Opin Ther Pat; 2022 Jun; 32(6):713-729. PubMed ID: 35343863
[TBL] [Abstract][Full Text] [Related]
38. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
McDermott U; Ames RY; Iafrate AJ; Maheswaran S; Stubbs H; Greninger P; McCutcheon K; Milano R; Tam A; Lee DY; Lucien L; Brannigan BW; Ulkus LE; Ma XJ; Erlander MG; Haber DA; Sharma SV; Settleman J
Cancer Res; 2009 May; 69(9):3937-46. PubMed ID: 19366796
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
Galvani E; Alfieri R; Giovannetti E; Cavazzoni A; La Monica S; Galetti M; Fumarola C; Bonelli M; Mor M; Tiseo M; Peters GJ; Petronini PG; Ardizzoni A
Curr Pharm Des; 2013; 19(5):818-32. PubMed ID: 22973953
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
